Literature DB >> 10992726

Secondary renal amyloidosis in adult onset Still's disease: case report and review of the literature.

Y B Oh1, S C Bae, J H Jung, T H Kim, J B Jun, S S Jung, I H Lee, D H Yoo, M H Park, S Y Kim.   

Abstract

We report a 25-year-old Korean woman with Adult onset Still's disease (AOSD) presented with renal amyloidosis, which had developed four years after disease onset. We successfully treated her with prednisolone, colchicine and cyclophosphamide. A review of the literature uncovered about 10 cases, most of which were treated by various regimens that resulted in poor outcomes. Renal amyloidosis should be suspected in patients with AOSD who have unexplained proteinuria. Although the mechanism of renal amyloid deposition is not well known, earlier histopathologic diagnosis and choice of regimen may affect prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 10992726      PMCID: PMC4531753          DOI: 10.3904/kjim.2000.15.2.131

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  13 in total

1.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

2.  Vascular renal AA amyloidosis in adult Still's disease.

Authors:  F Rivera; C M Gil; M T Gil; E Batlle-Gualda; M Trigueros; J Olivares
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

3.  Adult onset Still's disease: clinical experience with 18 patients over 15 years in northern India.

Authors:  P Bambery; R J Thomas; H S Malhotra; U Kaur; S R Bhusnurmath; S D Deodhar
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

4.  Adult Still's disease: manifestations, disease course, and outcome in 62 patients.

Authors:  J Pouchot; J S Sampalis; F Beaudet; S Carette; F Décary; M Salusinsky-Sternbach; R O Hill; A Gutkowski; M Harth; D Myhal
Journal:  Medicine (Baltimore)       Date:  1991-03       Impact factor: 1.889

5.  Adult onset Still's disease and related renal amyloidosis.

Authors:  D Wendling; P G Humbert; C Billerey; T Fest; J L Dupond
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

6.  Systemic amyloidosis in a patient with adult onset Still's disease.

Authors:  T Ishii; T Sasaki; T Muryoi; C Murai; A Hatakeyama; H Oosaki; A Yusa; T Kawanami; K Yoshinaga
Journal:  Intern Med       Date:  1993-01       Impact factor: 1.271

7.  Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease.

Authors:  B Fautrel; C Borget; S Rozenberg; O Meyer; X Le Loët; C Masson; A C Koeger; M F Kahn; P Bourgeois
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

8.  [Clinical studies on 14 cases of adult-onset Still's disease].

Authors:  M Hashimoto; M Shingu; I Ezaki; Y Yoshikawa; M Nobunaga
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  1995-02

Review 9.  Amyloidosis: prognosis and treatment.

Authors:  M A Gertz; R A Kyle
Journal:  Semin Arthritis Rheum       Date:  1994-10       Impact factor: 5.532

10.  Amyloidosis in adult onset Still's disease.

Authors:  T M Harrington; J J Moran; D E Davis
Journal:  J Rheumatol       Date:  1981 Sep-Oct       Impact factor: 4.666

View more
  3 in total

Review 1.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Retrospective study of 61 patients with adult-onset Still's disease admitted with fever of unknown origin in China.

Authors:  Pei-Dong Chen; Sheng-Lei Yu; Shu Chen; Xin-Hua Weng
Journal:  Clin Rheumatol       Date:  2011-07-20       Impact factor: 3.650

Review 3.  Mechanisms, biomarkers and targets for adult-onset Still's disease.

Authors:  Eugen Feist; Stéphane Mitrovic; Bruno Fautrel
Journal:  Nat Rev Rheumatol       Date:  2018-10       Impact factor: 20.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.